MedTrace Logo

Early Use of Ivabradine in Heart Failure

NCT03701880 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2018-10-11

No results posted yet for this study

Summary

The aim of the work is to Evaluate the efficacy, quality of life and safety of early addition of ivabradine to B-blocker in reduced EF heart failure patients after acute decompensation compared to the standard treatment.

Conditions

  • Heart Failure With Reduced Ejection Fraction
  • Decompensated Heart Failure

Interventions

DRUG

Ivabradine

Ivabradine is pacemaker current I(f) inhibitor thereby slowing heart rates without exhibiting negative inotropic effect on the myocardium or altering ventricular action potential

DRUG

Bisoprolol

Bisoprolol is beta-blocker

Sponsors & Collaborators

  • Sadat City University

    collaborator OTHER

  • Ain Shams University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-16
Primary Completion
2019-12-23
Completion
2019-12-23

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03701880 on ClinicalTrials.gov